Lamotrigin Orion (Lamotrigine)

Lamotrigine blocks voltage‑gated sodium channels in neurons, stabilising cell membranes and reducing excessive firing. This action also limits the release of excitatory neurotransmitters such as glutamate, which underlies its antiepileptic and mood‑stabilising properties.

The dosage of lamotrigine is individualised by the prescribing clinician. Treatment typically starts at a low dose and is increased gradually according to the patient’s response and tolerance, following established titration guidelines.

Lamotrigine is classified as Pregnancy Category D, indicating potential risk to the fetus. It should be used only when the therapeutic benefit justifies the risk. Limited data exist for breastfeeding; a prescriber should evaluate the risk‑benefit ratio for each case.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older agents such as carbamazepine, lamotrigine has a lower risk of drug‑induced hyponatremia and fewer cognitive side effects, but it carries a unique risk of severe skin reactions. Its efficacy in both epilepsy and bipolar disorder makes it a versatile option for patients needing dual‑indication therapy.

Lamotrigin Orion tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

The medication is taken orally, usually with a glass of water. Tablets may be swallowed with or without food, but consistent administration with respect to meals helps maintain stable plasma levels. Patients should follow the prescriber’s titration schedule closely.

The most critical safety concerns are severe cutaneous reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, which require immediate medical attention. Other serious risks include blood dyscrasias and, rarely, hepatic failure. Prompt reporting of any rash or systemic symptoms is essential.

Lamotrigine is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. Patients with a history of severe skin reactions to lamotrigine or related compounds should avoid its use. Caution is also advised for those with significant hepatic or renal impairment.